Insider Selling: ADMA Biologics (NASDAQ:ADMA) COO Sells $157,800.48 in Stock

ADMA Biologics Inc (NASDAQ:ADMA) COO Kaitlin Kestenberg-Messina sold 10,096 shares of the business’s stock in a transaction that occurred on Monday, March 9th. The stock was sold at an average price of $15.63, for a total transaction of $157,800.48. Following the completion of the transaction, the chief operating officer directly owned 466,600 shares of the company’s stock, valued at approximately $7,292,958. This represents a 2.12% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

ADMA Biologics Stock Performance

ADMA Biologics stock opened at $14.99 on Friday. ADMA Biologics Inc has a fifty-two week low of $13.76 and a fifty-two week high of $25.67. The firm’s fifty day moving average price is $16.69 and its 200-day moving average price is $16.72. The stock has a market cap of $3.57 billion, a P/E ratio of 24.98 and a beta of 0.51. The company has a debt-to-equity ratio of 0.16, a quick ratio of 3.74 and a current ratio of 6.71.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.20. ADMA Biologics had a return on equity of 37.52% and a net margin of 28.80%.The business had revenue of $139.16 million for the quarter, compared to the consensus estimate of $139.80 million. During the same quarter last year, the business posted $0.46 earnings per share. The company’s revenue for the quarter was up 18.4% on a year-over-year basis. On average, equities research analysts expect that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

Institutional Trading of ADMA Biologics

Institutional investors have recently made changes to their positions in the stock. Corient Private Wealth LLC grew its holdings in shares of ADMA Biologics by 58.0% in the fourth quarter. Corient Private Wealth LLC now owns 91,367 shares of the biotechnology company’s stock worth $1,667,000 after purchasing an additional 33,541 shares during the last quarter. Vident Advisory LLC raised its holdings in ADMA Biologics by 24.2% during the 4th quarter. Vident Advisory LLC now owns 270,492 shares of the biotechnology company’s stock valued at $4,934,000 after buying an additional 52,687 shares during the last quarter. First Citizens Bank & Trust Co. boosted its position in ADMA Biologics by 24.4% during the 4th quarter. First Citizens Bank & Trust Co. now owns 48,763 shares of the biotechnology company’s stock valued at $889,000 after buying an additional 9,576 shares during the period. Cim LLC boosted its position in ADMA Biologics by 3.2% during the 4th quarter. Cim LLC now owns 94,379 shares of the biotechnology company’s stock valued at $1,721,000 after buying an additional 2,893 shares during the period. Finally, nVerses Capital LLC bought a new stake in ADMA Biologics in the 4th quarter worth $395,000. Hedge funds and other institutional investors own 75.68% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on ADMA. Zacks Research raised shares of ADMA Biologics from a “hold” rating to a “strong-buy” rating in a research note on Monday, March 2nd. Wall Street Zen raised shares of ADMA Biologics from a “hold” rating to a “buy” rating in a report on Saturday, February 28th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of ADMA Biologics in a research note on Tuesday, December 23rd. Two equities research analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, ADMA Biologics has a consensus rating of “Buy” and an average target price of $32.00.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.